Various markers have been developed to diagnose and prognosticate breast cancer patients including tumor size, histopathological grade, lymph nodal metastasis, and immunohistochemical (IHC) markers namely estrogen receptor (ER), progesterone receptor (PR) and HER2/neu. This evidence concerns the gene ESR1 and breast carcinoma.